09.21.18
PCI Pharma Services made headlines with the announcement of their intention to acquire Sherpa Clinical Packaging, a provider of clinical trial material management services for clinical studies, including packaging, labeling, distribution, storage and returns and destruction services. Sherpa's facilities employ cold chain technologies that include handling products requiring labeling and kitting at frozen and refrigerated conditions.
PCI provides global molecule-to-market services that span contract development and manufacturing, including specialization in highly complex and potent drugs, clinical supply services and commercial packaging services. Their clinical services include drug development and manufacturing, packaging and labeling, storage and logistical services, including support for Cold Chain and Ultra Cold Chain down to -196°C. The company is strategically investing in the expansion of its global Clinical Services business and this marks its third acquisition in 12 months.
Contract Pharma spoke with Mark Paiz
PCI provides global molecule-to-market services that span contract development and manufacturing, including specialization in highly complex and potent drugs, clinical supply services and commercial packaging services. Their clinical services include drug development and manufacturing, packaging and labeling, storage and logistical services, including support for Cold Chain and Ultra Cold Chain down to -196°C. The company is strategically investing in the expansion of its global Clinical Services business and this marks its third acquisition in 12 months.
Contract Pharma spoke with Mark Paiz
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
